Brands: Dextrose · Dextrose Monohydrate
Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume - Medicaid only, not all-payer.
US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.
| Labeler | Type | Packages | Status |
|---|---|---|---|
| Baxter Healthcare Corporation | brand | 26 | SUPPLYING |
| Fresenius Kabi, USA LLC | generic | 17 | SUPPLYING |
| ICU Medical Inc. | unknown | 15 | SUPPLYING |
| Becton Dickinson and Company | unknown | 11 | SUPPLYING |
| Hospira, Inc. | brand | 5 | SUPPLYING |
| Medical Purchasing Solutions, LLC | repackager | 5 | SUPPLYING |
| HF Acquisition Co. LLC, DBA HealthFirst | repackager | 3 | SUPPLYING |
| ProPharma Distribution | relabeler | 2 | SUPPLYING |
| REMEDYREPACK INC. | repackager | 2 | SUPPLYING |
| Henry Schein, Inc. | relabeler | 2 | SUPPLYING |
| International Medication Systems, Limited | unknown | 1 | SUPPLYING |
Shortages, recalls, and registration changes attached to this drug concept.
Lack of Assurance of Sterility — Recalling firm: Fresenius Kabi USA, LLC — US Nationwide , Alaska, and Puerto Rico.
Lack of Assurance of Sterility — Recalling firm: Fresenius Kabi USA, LLC — US Nationwide , Alaska, and Puerto Rico.
Lack of Assurance of Sterility — Recalling firm: Fresenius Kabi USA, LLC — US Nationwide , Alaska, and Puerto Rico.
Dextrose Monohydrate 70% Injection — reported in shortage by Baxter Healthcare. Therapeutic category: Endocrinology/Metabolism, Gastroenterology, Other, Pediatric.
Dextrose Monohydrate 10% Injection — reported in shortage by Otsuka ICU Medical LLC. Therapeutic category: Endocrinology/Metabolism, Gastroenterology, Other, Pediatric.
Dextrose Monohydrate 10% Injection — reported in shortage by Fresenius Kabi USA, LLC. Therapeutic category: Endocrinology/Metabolism, Gastroenterology, Other, Pediatric.
Dextrose Monohydrate 10% Injection — reported in shortage by Baxter Healthcare. Therapeutic category: Endocrinology/Metabolism, Gastroenterology, Other, Pediatric.
Dextrose Monohydrate 5% Injection — reported in shortage by Baxter Healthcare. Therapeutic category: Endocrinology/Metabolism, Gastroenterology, Other, Pediatric.
Dextrose Monohydrate 5% Injection — reported in shortage by Otsuka ICU Medical LLC. Therapeutic category: Endocrinology/Metabolism, Gastroenterology, Other, Pediatric.
Dextrose Monohydrate 5% Injection — reported in shortage by Fresenius Kabi USA, LLC. Therapeutic category: Endocrinology/Metabolism, Gastroenterology, Other, Pediatric.
Dextrose Monohydrate 50% Injection — reported in shortage by Hospira, Inc., a Pfizer Company. Therapeutic category: Endocrinology/Metabolism, Gastroenterology, Pediatric.
Dextrose Monohydrate 50% Injection — reported in shortage by Amphastar Pharmaceuticals, Inc.. Therapeutic category: Endocrinology/Metabolism, Gastroenterology, Pediatric.
Lack of sterility assurance: bag has the potential to leak. — Recalling firm: Pfizer Inc. — USA Nationwide
Labeling: Incorrect or Missing Lot and/or expiration date. — Recalling firm: Pfizer Inc. — Nationwide within the United States including Puerto Rico.
Lack of Assurance of Sterility: Bags have the potential to leak. — Recalling firm: Baxter Healthcare Corporation — Nationwide, Puerto Rico and Saudi Arabia
Presence of Particulate Matter: human hair found within an internal sample syringe. — Recalling firm: Hospira Inc. — Nationwide in the USA and Puerto Rico
Presence of Particulate Matter: Confirmed customer compliants of finding an insect floating in the primary container of each product. — Recalling firm: Baxter Healthcare Corp. — Nationwide
Presence of Particulate Matter: Products recalled due to presence of particulate matter (metal) — Recalling firm: Baxter Healthcare Corp. — US, Puerto Rico, and Bermuda
Presence of Particulate Matter: Products recalled due to presence of particulate matter (metal) — Recalling firm: Baxter Healthcare Corp. — US, Puerto Rico, and Bermuda
Lack of Assurance of Sterility. Complaints were receive of missing closures and/or leaks which may compromise product sterility. — Recalling firm: Baxter Healthcare Corp. — Nationwide
Lack of Assurance of Sterility: there is a potential for solution to leak at the administrative port of the primary container. — Recalling firm: Hospira Inc. — Nationwide
Presence of Paticulate Matter; Baxter is issuing a voluntary recall for these IV solutions due to particulate matter found in the solution identified as polyester and cotton fibers, adhesive-like mixture, polyacetal particles, thermally degraded PVC, black polypropylene and human hair embedded in the plastic bag — Recalling firm: Baxter Healthcare Corp. — Nationwide, Puerto Rico, Singapore, Saudi Arabia and United Arab Emirates.
Lack of Assurance of Sterility: Specific lot numbers of these products have been identified for potential administration port leakage. The potential for leakage is the result of a manufacturing issue which occurred during the sealing of the closure assembly at the administration port. — Recalling firm: Baxter Healthcare Corp. — Nationwide & Puerto Rico
